골다공증 환자에 있어 연 1회 정주용 졸렌드론산 투여의 순응도 평가
Analysis of Adherence of Once-yearly Intravenous Zolendronic Acid for Osteoporosis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: To analyze the adherence of once-yearly intravenous zolendronic acid for osteoporosis. Materials and Methods: The subjects were 322 osteoporotic patients who received more than single infusion of zolendronic acid. On clinical assessment, we assessed adherence. The changes of bone mineral density (BMD) and bone turnover marker were measured before and after infusion. Results: Reinfusion rate was 48.4% (109/225) at second infusion, and 51.3% (41/80) at third infusion. Adverse event at each time was 161 (42.1%) cases, 30 (27.5%) cases, and 8 (19.5%) cases, respectively. The measured mean BMD change was significantly increased (P-value<0.001). Conclusions: In this study, once-yearly intravenous zolendronic acid for 2 years was safe and efficacious in terms of BMD and bone turnover marker. The adherence was higher than most published studies of adherence to oral bisphosphonates, but lower than optimal. Physicians should fully explain to patients about medications and educate to improve their adherence.
Abstract
Objectives: To analyze the adherence of once-yearly intravenous zolendronic acid for osteoporosis. Materials and Methods: The subjects were 322 osteoporotic patients who received more than single infusion of zolendronic acid. On clinical assessment, we assessed adherence. The changes of bone mineral density (BMD) and bone turnover marker were measured before and after infusion. Results: Reinfusion rate was 48.4% (109/225) at second infusion, and 51.3% (41/80) at third infusion. Adverse event at each time was 161 (42.1%) cases, 30 (27.5%) cases, and 8 (19.5%) cases, respectively. The measured mean BMD change was significantly increased (P-value<0.001). Conclusions: In this study, once-yearly intravenous zolendronic acid for 2 years was safe and efficacious in terms of BMD and bone turnover marker. The adherence was higher than most published studies of adherence to oral bisphosphonates, but lower than optimal. Physicians should fully explain to patients about medications and educate to improve their adherence.
참고문헌 (18)
- Randell AG, "Deterioration in quality of life following hip fracture: a prospective study", Osteoporos Int, 11, pp.460~466 (2000)
- Gabriel SE, "Direct medical costs attributable to osteoporotic fractures", Osteoporos Int, 13, pp.323~330 (2002)
- Bluic D, "Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women", JAMA, 301, pp.513~521 (2009)
- Wells GA, "Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, 23, pp.CD001155~ (2008)
- Wells G, "Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, 23, pp.CD004523~ (2008)
- Imaz I, "Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis", Osteoporos Int, 21, pp.1943~1951 (2010)
- Netelenbos JC, "Adherence and profile of non-persistence in patients treated for osteoporosis : a large-scale, long-term retrospective study in The Netherlands", Osteoporos Int, 22, pp.1537~1546 (2011)
- Gold DT, "Review of adherence to medications for the treatment of osteoporosis", Curr Osteoporos Rep, 4, pp.21~27 (2006)
- Cramer JA, "A systematic review of persistence and compliance with bisphosphonates for osteoporosis", Osteoporos Int, 18, pp.1023~1031 (2007)
- Lambrinoudaki I, "Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women", Clin Interv Aging, 3, pp.445~451 (2008)
- Siris ES, "Adherence to bisphosphonate therapy and fracture rates in osteoporotic women:relationship to vertebral and nonvertebral fractures from 2 US claims databases", Mayo Clin Proc, 81, pp.1013~1022 (2006)
- Huybrechts KF, "Assessment of compliance with osteoporosis treatment and its consequences in a managed care population", Bone, 38, pp.922~928 (2006)
- Reid IR, "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", N Engl J Med, 346, pp.653~661 (2002)
- Black DM, "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis", N Engl J Med, 356, pp.1809~1822 (2007)
- Caro JJ, "The impact of compliance with osteoporosis therapy on fracture rates in actual practice", Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 15(12), pp.1003~1008 (2004)
- Devine J, "A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System", Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 23, pp.1415~1424 (2012)
- Lee YK, "Persistence with intravenous zoledronate in elderly patients with osteoporosis", Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 23, pp.2329~2333 (2012)
- Romero Barco CM, "Biochemical markers in osteoporosis:usefulness in clinical practice", Reumatologia Clinica, 8, pp.149~152 (2012)